CAMBRIDGE, Mass., Aug. 21, 2025 /PRNewswire/ -- Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism Spectrum Disorder (ASD), Fragile X Syndrome ...
HENDERSON, Nev. (AP) -- Spectrum Pharmaceuticals Inc. said Thursday it completed its acquisition of Allos Therapeutics Inc., giving the combined company a third approved drug. Spectrum said 90 percent ...
BANGALORE, Sept 25 (Reuters) - Allos Therapeutics said U.S. health regulators granted accelerated approval for its drug Folotyn to treat one of the most deadly and aggressive types of white blood cell ...
Mundipharma agreed to pay $310.5 million in milestones, gaining rights outside the U.S. and Canada. Allos Therapeutics could see up to $360.5 million under a collaboration with Mundipharma to ...
TEL AVIV (MarketWatch) -- Allos Therapeutics Inc., the Westminster, Colo., biopharma focused on cancer drugs, agreed to be acquired by Spectrum Pharmaceuticals Inc. for $1.82 cash plus a contigent ...
The proposed merger between AMAG and Allos will be submitted to the respective stockholders of AMAG and Allos for their consideration. AMAG will file a Registration Statement on Form S-4 containing a ...
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results